➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Merck
Express Scripts
Medtronic
Boehringer Ingelheim

Last Updated: September 26, 2020

DrugPatentWatch Database Preview

Patent: 8,859,748

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,859,748
Title:Nucleic acid amplification primers for PCR-based clonality studies
Abstract: The invention relates to PCR-based clonality studies for among others early diagnosis of lymphoproliferative disorders. Provided is a set of nucleic acid amplification primers comprising a forward primer, or a variant thereof, and a reverse primer, or a variant thereof, capable of amplifying a rearrangement selected from the group consisting of a VH-JH IGH rearrangement, a DH-JH IGH rearrangement, a VK-JK IGK rearrangement, a VK/intron-Kde IGK rearrangement, a V.lamda.-J.lamda. IGL rearrangement, a V.beta.-J.beta. TCRB rearrangement, a D.beta.-J.beta. TCRB rearrangement, a V.gamma.-J.gamma. TCRG rearrangement, a V.delta.-J.delta. TCRD rearrangement, a D.delta.-D.delta. TCRD rearrangement, a D.delta.-J.delta. TCRD rearrangement, a V.delta.-D.delta. TCRD rearrangement, or a translocation selected from t(11;14)(BCL1-IGH) and t(14;18)(BCL2-IGH). The primers can be used in PCR-based clonality studies for early diagnosis of lymphoproliferative disorders and detection of minimal residual disease (MRD). Also provided is a kit comprising at least one set of primers of the invention.
Inventor(s): Van Dongen; Jacobus Johannes Maria (Vorden, NL), Langerak; Anthonie Willem (Barendrecht, NL), Schuuring; Eduardus Maria Dominicus (Groningen, NL), San Miquel; Jesus Fernando (Salamanca, ES), Garcia Sanz; Ramon (Salamanca, ES), Parreira; Antonio (Lisbon, PT), Smith; John Lewis (Wilts, GB), Lavender; Frances Louise (Hants, GB), Morgan; Gareth John (Surrey, GB), Evans; Paul Anthony Stuart (West Yorkshire, GB), Kneba; Michael (Westensee, DE), Hummel; Michael (Berlin, DE), Macintyre; Elizabeth Anne (Meudon, FR), Bastard; Christian (Ardouval, FR)
Assignee:
Application Number:10/531,106
Patent Claims:see list of patent claims

Details for Patent 8,859,748

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Boehringer Ingelheim
AstraZeneca
Express Scripts
Mallinckrodt
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.